1. Academic Validation
  2. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma

A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma

  • Gynecol Oncol. 2004 Sep;94(3):643-9. doi: 10.1016/j.ygyno.2004.06.026.
Nao Suzuki 1 Daisuke Aoki Shinji Oie Miwa Horiuchi Yuko Hasegawa Sachiko Ezawa Atsushi Suzuki Nobuyuki Susumu Fumihito Hosoi Kenji Kitazato Shiro Nozawa
Affiliations

Affiliation

  • 1 Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan. naos@sc.itc.keio.ac.jp
Abstract

Objectives: A novel retinobenzoic acid derivative, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), was reported to suppress the growth and invasion of human gastric Cancer or hepatocellular carcinoma by induction of Apoptosis. We examined the antitumor activity of TAC-101 against human ovarian carcinoma cell lines.

Methods: Apoptosis of human epithelial ovarian carcinoma-derived cell lines (RMG-I, RMG-II, RTSG, RMUG-S, RMUG-L, and KF) was investigated by detecting DNA laddering and was quantified by an enzyme-linked immunosorbent assay. Inhibition of Apoptosis was also examined using a Caspase Inhibitor. Furthermore, TAC-101 (8 mg kg(-1) day(-1) orally for 30 days) was investigated in nude mice with subcutaneous RMG-II tumors. A prominent apoptotic response to TAC-101 was observed. The antitumor effects of cisplatin (7 mg/kg intravenously on day 1) and paclitaxel (36 mg/kg intravenously on days 1 and 5) were also assessed for comparison.

Results: Apoptosis occurred in all of the cell lines (except KF) in a concentration-dependent manner after exposure to TAC-101 and was markedly induced in RMG-I and RMG-II cells (derived from ovarian clear cell adenocarcinomas). A Caspase Inhibitor blocked the induction of Apoptosis by TAC-101. The maximum inhibition of RMG-II tumor growth in nude mice by TAC-101, cisplatin, and paclitaxel was 45%, 34%, and 47%, respectively.

Conclusion: Oral TAC-101 shows potential as a novel antitumor agent for ovarian carcinoma, especially ovarian clear cell adenocarcinoma.

Figures
Products